UPDATE
: Monday, September 7, 2020
Home
Login
Mobile Version
All
Hospital
Pharma
Bio
Korea‘s Bio Industry
Device/ICT
Policy
People
Life science
Special
Innovation for Survival
Korea’s medical culture series
Korea’s New Candidate Drug Watch List
Special Series in Celebration of KBR's 1st Anniversary
Interview with foreign envoys
Special Series in Celebration of KBR’s 2nd Anniversary
Interview with global pharma
Special Series in Celebration of KBR’s 3rd Anniversary
Special Series in Celebration of KBR’s 4th Anniversary
ASCO 2020 Highlights
Opinion
Reporter’s Notebook
Search
트위터
페이스북
RSS
상단여백
제목보기
제목보기
제목+내용
Celltrion will use Oracle Health platform to streamline processes
Celltrion will use Oracle Health platforms to help streamline regulatory re...
by Marian Chu
|
2017-09-27 10:47
라인
Can Celltrion, Samsung make stable earnings with biosimilar?
Amid the intensifying competition to lower drug prices, market watchers pre...
by Nam Doo-hyun
|
2017-09-26 17:31
라인
Medifron aims high through R&D
Medifron said Friday that it would increase its capital by issuing new stoc...
by Lee Han-soo
|
2017-09-25 16:19
라인
Korea lags far behind in biomedical R&D: report
Korea’s investment in the biomedical research and development lags far behi...
by Nam Doo-hyun
|
2017-09-21 16:14
라인
Biosimilar prescriptions fall by the wayside in Korea
Biosimilar uptake in the Korean market has been dismal, according to data a...
by Marian Chu
|
2017-09-21 14:56
라인
Samsung Bioepis gets additional approval for its biosimilar
Amid the controversy caused by MSD Korea’s alleged decision to cease promot...
by Lee Hye-seon
|
2017-09-21 12:03
라인
MSD dissolves promotion team for Samsung Bioepis’ biosimilars
MSD Korea has dissolved its Samsung Bioepis’s biosimilar promotion team and...
by Lee Han-soo
|
2017-09-21 11:58
라인
Sillajen emerges as biggest beneficiary of preferential listing
Sillajen has emerged as the most successful case of the preferential listin...
by Nam Doo-hyun
|
2017-09-20 17:22
라인
Samsung Bioepis gets nods for phase 3 trials to treat macular degeneration
Samsung Bioepis said Tuesday that it has received Ministry of Food and Drug...
by Lee Han-soo
|
2017-09-19 17:39
라인
Korean biopharmaceutical industry ranked 2nd among emerging countries
The Korean biopharmaceutical industry ranked second only to Singapore regar...
by Marian Chu
|
2017-09-19 10:37
라인
EU approvals for Samsung Bioepis push up share prices
Investors are showing higher expectation for Samsung Bioepis, a Samsung Gro...
by Nam Doo-hyun
|
2017-09-18 14:45
라인
Genexin, Handok presents persistent growth hormone clinical trial results
Genexin and Handok have announced the intermediate results of phase 2 clini...
by Lee Han-soo
|
2017-09-18 14:39
라인
Celltrion in controversy over sexual harassment case
Celltrion found itself embroiled in a controversial situation afters CEO Se...
by Lee Han-soo
|
2017-09-15 18:11
라인
‘Knowledge’ is core ability for bio industrialists, survey says
“Knowledge” is the most important element for people engaged in bio and hea...
by Nam Doo-hyun
|
2017-09-15 16:28
라인
Access Bio, PFSCM sign supply agreement for malaria kit
Access Bio said Friday that it has signed a supply agreement of partnership...
by Lee Han-soo
|
2017-09-15 14:52
라인
‘BIOplus Incheon 2017’ shares product-developing know-how
BIOplus Incheon 2017 successfully finished their second annual global confe...
by Lee Han-soo
|
2017-09-14 11:14
라인
Medipost to commercialize new stem cell-culture tech
Medipost announced Wednesday that it has acquired a domestic patent for com...
by Constance Williams
|
2017-09-14 10:38
라인
Hanall Biopharma made $81-million technology export to China
Hanall Biopharma said Tuesday it has licensed out two new bio drugs under d...
by Lee Hye-seon
|
2017-09-13 13:23
라인
New VC investments in bio, medical fields fall sharpest in H1
New venture capital investments in bio and medical industries have fallen m...
by Nam Doo-hyun
|
2017-09-13 13:23
라인
Celltrion presents Herzuma’s clinical results in Europe
Celltrion said Friday that it has presented the results of the clinical saf...
by Lee Han-soo
|
2017-09-11 12:19
-
이전
21
22
23
24
25
26
27
28
29
30
-
176 civic groups furious over government-doctors deal
Amgen Korea wins new indication for acute lymphoblastic leukemia drug
UBcare wins patent for tech to monitor suspected infectious diseases
SCM Lifescience punished for delaying adverse reaction report
176 civic groups furious over government-doctors deal
Amgen Korea wins new indication for acute lymphoblastic leukemia drug
UBcare wins patent for tech to monitor suspected infectious diseases
SCM Lifescience punished for delaying adverse reaction report
여백
Most viewed
1
‘Cyramza helped improve gastric cancer treatment in Korea’
2
‘Reduced-dose prasugrel effective for ACS patients undergoing PCI’
3
Amgen Korea wins new indication for acute lymphoblastic leukemia drug
4
SNUBH develops AI model predicting patients at risk of cerebral aneurysm
5
Novavax releases encouraging phase-1 results on Covid-19 vaccine candidate
6
LG Chem, SK Bioscience end sales partnership with Daewoong
7
UBcare wins patent for tech to monitor suspected infectious diseases
8
176 civic groups furious over government-doctors deal
9
Recovered Covid-19 patients suffer from aftereffects – for long
10
Regulator OKs JW Pharma's rheumarthritis drug for treating giant cell arteries
여백
Opinion
[Column] Correct diagnosis leads to proper treatment
[Column] How ongoing doctors’ strike is different from 20 years ago
A Korean-American Doctor asks: Is Korea truly in 2020?
여백
Back to Top